Copyright
©The Author(s) 2022.
World J Clin Cases. Nov 6, 2022; 10(31): 11411-11418
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11411
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11411
Table 3 Vaccine features and antibody levels of the study population
| Characteristic | Healthy | Cancer | P value |
| Antibody level (mean ± SD) | 31.6 ± 4.8 | 25.8 ± 3.2 | < 0.001 |
| Seropositivity | < 0.001 | ||
| Positive (≥ 10 AU/mL) | 96.3% (207/215) | 83.3% (110/132) | |
| Negative (< 10 AU/mL) | 3.7% (8/215) | 16.7% (22/132) | |
| Type of vaccine | 0.206 | ||
| Sinovac | 97.0% (159/164) | 83.2% (89/107) | |
| Beijing biological | 95.5% (42/44) | 78.9% (15/19) | |
| Wuhan biological | 85.7% (6/7) | 85.7% (6/7) |
- Citation: Cai SW, Chen JY, Wan R, Pan DJ, Yang WL, Zhou RG. Efficacy and safety profile of two-dose SARS-CoV-2 vaccines in cancer patients: An observational study in China. World J Clin Cases 2022; 10(31): 11411-11418
- URL: https://www.wjgnet.com/2307-8960/full/v10/i31/11411.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i31.11411